Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...
The alternative complement pathway plays a key role in the pathogenesis of IgA nephropathy. Iptacopan specifically binds to factor B and inhibits the alternative pathway. In this phase 3, double-blind ...
SEATTLE--(BUSINESS WIRE)--Omeros Corporation today announced that OMS906 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of paroxysmal nocturnal ...
Severe posttransfusion hyperhemolysis in a sickle cell patient produced profound anemia and lactic acidosis; terminal complement blockade with eculizumab stabilized hemolysis and enabled recovery.
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial (NCT06209177) of ARO-CFB, the ...
Novartis Pharmaceuticals Canada Inc. ("Novartis Canada") announced today that Health Canada has granted a Notice of Compliance (NOC) for Fabhalta® (iptacopan capsules) for the treatment of adult ...
With Alzheimer’s disease therapies finally reaching the market and hundreds of active clinical trials for therapies and diagnostics, it seems like every week brings another potential avenue to explore ...
Verywell Health on MSN
6 types of treatment for complement 3 glomerulopathy
Medically reviewed by Matthew Wosnitzer, MD Managing complement 3 glomerulopathy involves several treatment options aimed at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results